Sugi Predict

Sugi Predict / Compounds / SCHEMBL68886

SCHEMBL68886

SCHEMBL68886

Cc1ccc2c(c1)C(=O)CCO2

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ RAB9A P51151 2/20 0.51
▸ KMT2A Q03164 1/20 0.51
▸ KDM4E B2RXH2 4/20 0.50
▸ MAOB P27338 4/20 0.50
▸ ATM Q13315 3/20 0.50
▸ HTT P42858 1/20 0.50
▸ MAOA P21397 1/20 0.50
▸ GRM5 P41594 4/20 0.47
▸ CYP19A1 P11511 1/20 0.45
▸ RAD52 P43351 1/20 0.44
▸ NPC1 O15118 2/20 0.43
▸ ALDH1A1 P00352 2/20 0.43
▸ PIK3CA P42336 2/20 0.43
▸ PIK3CB P42338 2/20 0.43
▸ PIK3CG P48736 2/20 0.43
▸ GAA P10253 1/20 0.43
▸ MAPT P10636 1/20 0.43
▸ HSD17B10 Q99714 1/20 0.43
▸ MMP12 P39900 1/20 0.41
▸ HPGD P15428 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Ethylene Glycol SCHEMBL9338892 0.92 MAOB (0.48) RAB9AKMT2AKDM4EMAOBATM
Thianthrene SCHEMBL30428045 0.88 KDM4E (0.46) RAB9AKMT2AKDM4EMAOBATM
SCHEMBL14552635 0.86 MAOB (0.49) RAB9AKMT2AKDM4EMAOBATM
SCHEMBL768839 0.85 MAOB (0.64) RAB9AMAOBMAOAGRM5CYP19A1
SCHEMBL31303039 0.85 MAOB (0.64) RAB9AMAOBMAOAGRM5CYP19A1
SCHEMBL25873334 0.84 MAOB (0.46) RAB9AKMT2AKDM4EMAOBATM
SCHEMBL27872271 0.84 MAOB (0.43) RAB9AKMT2AKDM4EMAOBATM
Hydrochloric Acid SCHEMBL27916631 0.84 MAOB (0.62) RAB9AMAOBMAOAGRM5CYP19A1
SCHEMBL27872270 0.82 MAOB (0.55) MAOBMAOAGRM5
SCHEMBL95448 0.81 MMP12 (0.51) RAB9AKMT2AKDM4EMAOBATM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 241 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111518117-B 1, 2-oxazinopyran compound and preparation method and application thereof 西安凯新生物科技有限公司 2022-08-26 — — CN claimed
CN-111518117-A 1, 2-oxazinopyran compound and preparation method and application thereof 朱翠萍 2020-08-11 — — CN claimed
EP-3856734-B1 REAGENTS AND PROCESS FOR DIRECT C-H FUNCTIONALIZATION STUDIENGESELLSCHAFT KOHLE GGMBH (DE) 2025-09-24 — — EP disclosed
WO-2025054431-A1 BENZO-FUSED HETEROCYCLIC COMPOUNDS AND USES THEREOF XENON PHARMACEUTICALS INC. (CA) 2025-03-13 — — WO disclosed
WO-2024189607-A1 METHODS AND BIOAVAILABLE HIGHLY PERMEABLE COMPOUNDS FOR DISEASES TREATMENT DIDENKO KIRILL (MX) 2024-09-19 — — WO disclosed
US-12065422-B2 Reagents and process for direct C—H functionalization STUDIENGESELLSCHAFT KOHLE GGMBH (DE) 2024-08-20 — — US disclosed
WO-2024140431-A1 COMPOUNDS COMPRISING HETEROARYL RINGS AND COMPOSITIONS AND METHODS THEREOF IONGEN THERAPEUTICS CO., LTD. (CN) 2024-07-04 — — WO disclosed
US-11807633-B2 Chromene derivatives as inhibitors of TCR-Nck interaction ARTAX BIOPHARMA INC. (US) 2023-11-07 — — US disclosed
US-20230286917-A1 HISTONE DEMETHYLASE INHIBITORS CELGENE QUANTICEL RESEARCH, INC. (US) 2023-09-14 — — US disclosed
US-20230227425-A1 REAGENTS AND PROCESS FOR DIRECT C-H FUNCTIONALIZATION STUDIENGESELLSCHAFT KOHLE MBH (DE) 2023-07-20 — — US disclosed
US-20230227425-A1 REAGENTS AND PROCESS FOR DIRECT C-H FUNCTIONALIZATION STUDIENGESELLSCHAFT KOHLE MBH (DE) 2023-07-20 — — US disclosed
US-5322847-A Inhibit platelet activating factor, block leukotriene D4 receptors PFIZER INC. (US) 1994-06-21 — — US disclosed
EP-0533695-A1 IMIDAZO (4,5-c) PYRIDINES WITH PAF ANTAGONIST ACTIVITY. PFIZER (US) 1993-03-31 — — EP disclosed
WO-1991017163-A1 IMIDAZO (4,5-c) PYRIDINES WITH PAF ANTAGONIST ACTIVITY PFIZER INC. (US) 1991-11-14 — — WO disclosed
US-4992564-A Preparation of 6-substituted 4-chromanones MALLINCKRODT, INC. (US) 1991-02-12 — — US disclosed
US-4918203-A Preparation of 6-substituted 4-chromanones MALLINCKRODT INC. 1990-04-17 — — US disclosed
EP-0228172-B1 PREPARATION OF 6-SUBSTITUTED 4-CHROMANONES Mallinckrodt, Inc. (a Delaware corporation) (US) 1990-03-07 — — EP disclosed
EP-0228172-A1 Preparation of 6-substituted 4-chromanones Mallinckrodt, Inc. (a Delaware corporation) (US) 1987-07-08 — — EP disclosed
EP-0087858-A1 New chromanone compounds and pharmaceutical compositions containing them NIPPON ZOKI PHARMACEUTICAL CO. LTD. (JP) 1983-09-07 — — EP disclosed
US-4261988-A ANTICHOLESTEROL AGENTS USED IN ANIMAL HUSBANDRY BAYER AKTIENGESELLSCHAFT (DE) 1981-04-14 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230227425-A1 REAGENTS AND PROCESS FOR DIRECT C-H FUNCTIONALIZATION CFH, DOHH, CTSH RAB9A 1649/4885KMT2A 867/4885KDM4E 739/4885
US-11807633-B2 Chromene derivatives as inhibitors of TCR-Nck interaction NCK1, NCKAP1, NCKAP1L RAB9A 2488/4885KMT2A 3142/4885KDM4E 3149/4885
US-20230286917-A1 HISTONE DEMETHYLASE INHIBITORS KDM1B, KDM5A, KDM1A RAB9A 3032/4885KMT2A 45/4885KDM4E 26/4885
US-12065422-B2 Reagents and process for direct C—H functionalization CFH, DOHH, CTSH RAB9A 1628/4885KMT2A 934/4885KDM4E 698/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.